U.S. Healthtech Stock News

MannKind (MNKD) has wrapped up FY 2025 with fourth quarter revenue of US$112 million and a basic EPS loss of US$0.05, setting a clear focal point for investors watching how its income statement is evolving. Over recent periods the company has seen revenue move from US$70 million in Q3 2024 to US$82 million in Q3 2025, while quarterly EPS has ranged from US$0.04 in Q1 2025 to a small profit of US$0.03 in Q3 2025 before this latest loss. This puts the spotlight firmly on how durable its margins...

If you are wondering whether T. Rowe Price Group shares offer fair value at around US$94.63, this article walks through what the numbers suggest and how to think about the price you are paying. The stock has seen a 0.8% decline over the last week, a 10.1% decline over the last month, a 9.6% decline year to date, and a 5.7% decline over the last year. The 3 year and 5 year returns stand at a 4.0% decline and a 31.8% decline respectively. Recent market attention on asset managers has focused...

OPKO Health (OPK) just closed out FY 2025 with Q4 revenue of US$148.45 million, basic EPS of a US$0.04 loss, and quarterly net income excluding extra items showing a loss of US$31.26 million, set against trailing twelve month revenue of US$606.88 million and a loss of US$225.68 million on the same basis. The company has seen quarterly revenue move from US$183.64 million and basic EPS of US$0.02 in Q4 2024 to US$148.45 million and basic EPS of a US$0.04 loss in Q4 2025, while trailing twelve...

Alexander & Baldwin (ALEX) has wrapped up FY 2025 with fourth quarter revenue of US$43.8 million and basic EPS of US$0.05, alongside trailing twelve month revenue of US$206.7 million and EPS of US$0.89. Over the last six quarters, the company has seen quarterly revenue move from US$63.2 million in Q4 2024 to US$56.8 million in Q1 2025 and down to US$43.8 million in Q4 2025, while quarterly EPS moved from US$0.18 to US$0.29 and then US$0.05. This sets up a mixed backdrop for a stock trading at...

Opendoor Technologies (NasdaqGS:OPEN) is reporting progress on its turnaround, with faster inventory turns, more home acquisitions, and early benefits from AI tools. The company recently highlighted a 46% increase in home acquisitions, better resale velocity, and tighter inventory management despite a tough housing market. Management is also rolling out an AI driven operating model and a beta mortgage product as it leans into an e commerce style platform for residential real estate. For...

In February 2026, Camtek Ltd. reported its fourth‑quarter 2025 results, with sales rising to US$128.12 million and net income to US$35.9 million, alongside higher quarterly earnings per share than a year earlier. Despite full‑year 2025 net income dropping to US$50.72 million even as sales grew to US$496.07 million, management issued upbeat 2026 guidance, highlighting expected double‑digit revenue growth supported by a solid backlog and customer pipeline. We’ll now examine how Camtek’s...

Applied Digital (NasdaqGS:APLD) faces material risk from heavy reliance on a single major tenant, CoreWeave, for a substantial share of its future revenue. CoreWeave is currently unprofitable and highly leveraged, which raises concerns about its long term ability to meet multi year commitments. Many of Applied Digital’s leases include termination clauses that allow tenants to walk away without penalty if construction milestones are not met. The company has taken on a large amount of debt...

Zai Lab (NasdaqGM:ZLAB) closed out FY 2025 with fourth quarter revenue of US$127.6 million and a basic EPS loss of US$0.46. Trailing 12 month figures show revenue of US$460.2 million and a basic EPS loss of US$1.60. Over recent periods the company has seen revenue range from US$102.3 million in Q3 2024 to US$127.6 million in Q4 2025, with quarterly basic EPS losses moving between US$0.33 and US$0.80. This sets up a picture where scale is building but margins are still under pressure for...

TPG (TPG) stock has come under pressure after investors focused on its £44 million exposure to failed UK mortgage lender Market Financial Solutions, which faces a reported £930 million collateral shortfall. See our latest analysis for TPG. The £44 million exposure to Market Financial Solutions comes on top of other recent headlines for TPG, including its role in a US$450 million Xerox joint venture financing and interest in the MarineMax sale process. Despite those developments, the share...

Alta Equipment Group (ALTG) has reported fourth quarter FY 2025 revenue of US$509.1 million with a basic EPS loss of US$0.39, setting the tone for a year where the business stayed focused on scale while earnings remained in the red. The company has seen quarterly revenue move from US$448.8 million in Q3 2024 to US$498.1 million in Q4 2024, then to US$423.0 million in Q1 2025 and up to US$509.1 million in Q4 2025, while basic EPS over that stretch ranged from a loss of US$0.34 to a loss of...

TeraWulf (WULF) closed FY 2025 with Q4 revenue of US$35.8 million and a basic EPS loss of US$0.30, alongside a trailing twelve month revenue base of US$168.5 million and a full year EPS loss of US$1.66. Over the last six reported quarters, revenue has ranged from US$27.1 million in Q3 2024 to US$50.6 million in Q3 2025, while quarterly basic EPS losses have moved between US$0.05 and US$1.13. This gives investors a clear picture of a business still working through heavy losses. With trailing...

Why MGIC Investment (MTG) Is On Investors’ Radar Today MGIC Investment (MTG) is drawing attention after recent trading left the mortgage insurer’s shares roughly flat over the past month, with a modest loss over the past 3 months and a decline year to date. See our latest analysis for MGIC Investment. At a share price of US$26.53, MGIC Investment’s short term share price return over the past 90 days has been negative, while its 1 year and 5 year total shareholder returns remain firmly...

Hudson Pacific Properties (HPP) closed out FY 2025 with Q4 revenue of US$256.0 million and basic EPS of US$4.31 loss, while trailing twelve month revenue came in at US$831.1 million alongside a TTM basic EPS of US$12.81 loss. This gives investors a clear snapshot of pressure on per share results. Over recent periods, the company has seen quarterly revenue shift from US$208.8 million in Q4 2024 to US$256.0 million in Q4 2025, with basic EPS moving from a loss of US$8.28 per share to a loss of...

Delek US Holdings (DK) closed out FY 2025 with Q4 revenue of US$2,429.4 million and basic EPS of US$1.32, alongside net income from continuing operations of US$79.5 million. Over the past few quarters, revenue has moved between US$2,641.9 million and US$2,887 million while basic EPS has swung from a loss of US$2.78 in Q1 2025 to a profit of US$2.96 in Q3 2025 and then US$1.32 in Q4, highlighting the sensitivity of margins to refining conditions and product mix. See our full analysis for Delek...

C4 Therapeutics (CCCC) just posted its FY 2025 Q4 numbers, with revenue of US$11.0 million and a quarterly loss translating to basic EPS of US$0.18, set against a trailing twelve month loss of US$105.0 million and EPS of US$1.27 on revenue of US$35.9 million. Over recent quarters, the company has seen revenue move between US$5.2 million and US$15.4 million, while quarterly EPS has ranged from US$0.35 to US$0.49 and quarterly losses from US$24.7 million to US$34.6 million. The key question for...

Cigna Group (CI) has wrapped up FY 2025 with fourth quarter revenue of US$72.5b, basic EPS of US$4.67 and net income of US$1,234m, putting a clear spotlight on how the year’s strong headline numbers translate into underlying profitability. The company has seen quarterly revenue move from US$65.6b in Q4 2024 to US$72.5b in Q4 2025, with basic EPS shifting from US$5.13 to US$4.67 over the same period. Trailing 12 month EPS reached US$22.33 on net income of US$5,957m, highlighting a year in...

Golden Entertainment (GDEN) has wrapped up FY 2025 with Q4 revenue of US$155.6 million and a basic EPS loss of US$0.33, alongside net income excluding extra items of a US$8.5 million loss. Over recent periods, the company has seen quarterly revenue move between US$154.8 million and US$164.2 million, while EPS has swung from a profit of US$0.18 in Q3 2024 to a loss of US$0.33 in Q4 2025. This leaves investors watching how quickly margins can stabilize from here. See our full analysis for...

Castle Biosciences (CSTL) has wrapped up FY 2025 with Q4 revenue of US$87 million and a basic EPS loss of US$0.08, alongside trailing twelve month revenue of US$344.2 million and a basic EPS loss of US$0.83. Over recent periods, the company has seen quarterly revenue range from US$83 million to US$88 million, while basic EPS has moved between a loss of US$0.90 and a profit of US$0.16. This sets the stage for investors to focus closely on how those revenue levels translate into sustainable...

What the latest earnings mean for W.W. Grainger (GWW) investors W.W. Grainger (GWW) recently posted quarterly results that topped expectations on both earnings and revenue, while management laid out full year guidance that points to higher projected EPS and sales compared with its latest reported figures. See our latest analysis for W.W. Grainger. At a share price of $1,144.73, W.W. Grainger has seen a 20.67% 90 day share price return and a 68.51% three year total shareholder return,...

FIGS (FIGS) closed out FY 2025 with Q4 revenue of US$201.9 million and basic EPS of US$0.11, while trailing twelve month EPS sat at US$0.21 on US$631.1 million of revenue. This came alongside a very large year over year earnings increase and a trailing net profit margin of 5.4% versus 0.5% a year earlier. The company has seen quarterly revenue move from US$151.8 million and EPS of US$0.01 in Q4 2024 to US$201.9 million and EPS of US$0.11 in Q4 2025, putting improving profitability front and...

Walker & Dunlop FY 2025 earnings snapshot Walker & Dunlop (WD) closed out FY 2025 with Q4 revenue of US$320.9 million and a basic EPS loss of US$0.39, as net income excluding extra items came in at a loss of US$13.1 million. The company reported quarterly revenue of US$321.0 million and EPS of US$1.32 in Q4 2024, compared with US$320.9 million and an EPS loss of US$0.39 in Q4 2025. Trailing twelve month revenue was US$1.2 billion and basic EPS was US$1.71. With margins under pressure and a...

Alignment Healthcare (ALHC) has wrapped up FY 2025 with Q4 revenue of US$1.0b and a basic EPS loss of US$0.05, alongside trailing 12 month revenue of US$4.0b and a near breakeven basic EPS of US$0.00. The company has seen quarterly revenue move from US$701.2m and a basic EPS loss of US$0.16 in Q4 2024 to US$1.0b and a basic EPS loss of US$0.05 in Q4 2025, while trailing 12 month basic EPS shifted from a loss of US$0.67 in Q4 2024 to a small loss of US$0.00 in Q4 2025, putting the focus firmly...

Cytek Biosciences (CTKB) closed out FY 2025 with Q4 revenue of US$62.1 million and a basic EPS loss of US$0.34, as net income excluding extra items came in at a loss of US$44.1 million. The company has seen quarterly revenue range from US$41.5 million to US$62.1 million over the past year, while basic EPS moved from a profit of US$0.07 in Q4 2024 to a loss of US$0.34 in Q4 2025. This shift highlights a clear pressure point on profitability. For investors, the latest print keeps the focus...

TriMas (TRS) has wrapped up FY 2025 with fourth quarter revenue of US$155.5 million and basic EPS of US$1.84, while trailing twelve month EPS stands at US$1.79 on revenue of US$645.7 million and a net profit margin of 11.2% versus 2.6% a year earlier. Over recent periods, the company has seen quarterly revenue range from US$228.1 million in Q4 2024 to US$274.8 million in Q2 2025, with basic EPS moving from US$0.14 in Q4 2024 to US$0.41 in Q2 2025 and US$0.31 in Q1 2025. With earnings over the...